Logo image of 22UA.DE

BIONTECH SE-ADR (22UA.DE) Stock Fundamental Analysis

FRA:22UA - Deutsche Boerse Ag - US09075V1026 - ADR - Currency: EUR

112.9  -4.9 (-4.16%)

Fundamental Rating

4

Taking everything into account, 22UA scores 4 out of 10 in our fundamental rating. 22UA was compared to 72 industry peers in the Biotechnology industry. 22UA is in great health and has no worries on liquidiy or solvency at all, but the profibility rating is only average. 22UA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

22UA had negative earnings in the past year.
22UA had a positive operating cash flow in the past year.
22UA had positive earnings in 4 of the past 5 years.
In multiple years 22UA reported negative operating cash flow during the last 5 years.
22UA.DE Yearly Net Income VS EBIT VS OCF VS FCF22UA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5B 10B

1.2 Ratios

Looking at the Return On Assets, with a value of -2.08%, 22UA is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
The Return On Equity of 22UA (-2.44%) is better than 78.13% of its industry peers.
Industry RankSector Rank
ROA -2.08%
ROE -2.44%
ROIC N/A
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
22UA.DE Yearly ROA, ROE, ROIC22UA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 0 50 100 150

1.3 Margins

22UA's Profit Margin has improved in the last couple of years.
22UA has a Gross Margin of 87.71%. This is amongst the best in the industry. 22UA outperforms 82.81% of its industry peers.
22UA's Gross Margin has been stable in the last couple of years.
The Profit Margin and Operating Margin are not available for 22UA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 87.71%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
22UA.DE Yearly Profit, Operating, Gross Margins22UA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 0 50 -50 -100 -150

More info and screens

8

2. Health

2.1 Basic Checks

22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for 22UA has been reduced compared to 1 year ago.
22UA has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, 22UA has a worse debt to assets ratio.
22UA.DE Yearly Shares Outstanding22UA.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M 200M
22UA.DE Yearly Total Debt VS Total Assets22UA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B

2.2 Solvency

22UA has an Altman-Z score of 7.00. This indicates that 22UA is financially healthy and has little risk of bankruptcy at the moment.
Looking at the Altman-Z score, with a value of 7.00, 22UA belongs to the top of the industry, outperforming 90.63% of the companies in the same industry.
22UA has a debt to FCF ratio of 0.25. This is a very positive value and a sign of high solvency as it would only need 0.25 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 0.25, 22UA belongs to the top of the industry, outperforming 96.88% of the companies in the same industry.
A Debt/Equity ratio of 0.01 indicates that 22UA is not too dependend on debt financing.
The Debt to Equity ratio of 22UA (0.01) is better than 82.81% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.25
Altman-Z 7
ROIC/WACCN/A
WACC6.78%
22UA.DE Yearly LT Debt VS Equity VS FCF22UA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 0 5B 10B 15B 20B

2.3 Liquidity

A Current Ratio of 7.33 indicates that 22UA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 7.33, 22UA belongs to the top of the industry, outperforming 89.06% of the companies in the same industry.
A Quick Ratio of 7.21 indicates that 22UA has no problem at all paying its short term obligations.
22UA's Quick ratio of 7.21 is amongst the best of the industry. 22UA outperforms 89.06% of its industry peers.
Industry RankSector Rank
Current Ratio 7.33
Quick Ratio 7.21
22UA.DE Yearly Current Assets VS Current Liabilites22UA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 5B 10B 15B 20B

More info and screens

3

3. Growth

3.1 Past

22UA shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -117.52%.
22UA shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 279.64% yearly.
The Revenue for 22UA has decreased by -54.07% in the past year. This is quite bad
Measured over the past years, 22UA shows a very strong growth in Revenue. The Revenue has been growing by 97.22% on average per year.
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%

3.2 Future

The Earnings Per Share is expected to decrease by -17.80% on average over the next years. This is quite bad
22UA is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -4.48% yearly.
EPS Next Y-183.58%
EPS Next 2Y-69.98%
EPS Next 3Y-42.65%
EPS Next 5Y-17.8%
Revenue Next Year-38.3%
Revenue Next 2Y-22.61%
Revenue Next 3Y-15.82%
Revenue Next 5Y-4.48%

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
22UA.DE Yearly Revenue VS Estimates22UA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 5B 10B 15B
22UA.DE Yearly EPS VS Estimates22UA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 10 20 30

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

22UA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year 22UA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
22UA.DE Price Earnings VS Forward Price Earnings22UA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50

4.2 Price Multiples

Compared to the rest of the industry, the Price/Free Cash Flow ratio of 22UA indicates a rather cheap valuation: 22UA is cheaper than 82.81% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF 27.91
EV/EBITDA N/A
22UA.DE Per share data22UA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

22UA's earnings are expected to decrease with -42.65% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-69.98%
EPS Next 3Y-42.65%

More info and screens

0

5. Dividend

5.1 Amount

22UA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

BIONTECH SE-ADR

FRA:22UA (2/4/2025, 7:00:00 PM)

112.9

-4.9 (-4.16%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2024-11-04/bmo
Earnings (Next)N/A N/A
Inst Owners19.03%
Inst Owner ChangeN/A
Ins Owners2.05%
Ins Owner ChangeN/A
Market Cap27.07B
Analysts77.78
Price Target135.86 (20.34%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)44.04%
Min EPS beat(2)-62.82%
Max EPS beat(2)150.91%
EPS beat(4)1
Avg EPS beat(4)11.69%
Min EPS beat(4)-62.82%
Max EPS beat(4)150.91%
EPS beat(8)5
Avg EPS beat(8)271.9%
EPS beat(12)8
Avg EPS beat(12)194.11%
EPS beat(16)12
Avg EPS beat(16)219.92%
Revenue beat(2)1
Avg Revenue beat(2)47.3%
Min Revenue beat(2)-13.02%
Max Revenue beat(2)107.62%
Revenue beat(4)1
Avg Revenue beat(4)4.24%
Min Revenue beat(4)-56.98%
Max Revenue beat(4)107.62%
Revenue beat(8)2
Avg Revenue beat(8)-8.54%
Revenue beat(12)5
Avg Revenue beat(12)4.91%
Revenue beat(16)9
Avg Revenue beat(16)15.52%
PT rev (1m)1.49%
PT rev (3m)10.79%
EPS NQ rev (1m)-16.01%
EPS NQ rev (3m)-81.45%
EPS NY rev (1m)-2.4%
EPS NY rev (3m)-30.31%
Revenue NQ rev (1m)3.74%
Revenue NQ rev (3m)-36.86%
Revenue NY rev (1m)0.33%
Revenue NY rev (3m)-1.14%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 8.9
P/FCF 27.91
P/OCF 17.79
P/B 1.42
P/tB 1.51
EV/EBITDA N/A
EPS(TTM)-1.96
EYN/A
EPS(NY)-3.41
Fwd EYN/A
FCF(TTM)4.04
FCFY3.58%
OCF(TTM)6.35
OCFY5.62%
SpS12.68
BVpS79.73
TBVpS74.53
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.08%
ROE -2.44%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 87.71%
FCFM 31.9%
ROA(3y)36.53%
ROA(5y)17.56%
ROE(3y)46.06%
ROE(5y)20.59%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)61.51%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3Y98.55%
PM growth 5YN/A
GM growth 3Y-1.33%
GM growth 5Y-1.09%
F-Score2
Asset Turnover0.14
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.25
Debt/EBITDA N/A
Cap/Depr 261.47%
Cap/Sales 18.15%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.33
Quick Ratio 7.21
Altman-Z 7
F-Score2
WACC6.78%
ROIC/WACCN/A
Cap/Depr(3y)295.05%
Cap/Depr(5y)262.38%
Cap/Sales(3y)7.13%
Cap/Sales(5y)20.83%
Profit Quality(3y)216.26%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-117.52%
EPS 3Y279.64%
EPS 5YN/A
EPS Q2Q%20.9%
EPS Next Y-183.58%
EPS Next 2Y-69.98%
EPS Next 3Y-42.65%
EPS Next 5Y-17.8%
Revenue 1Y (TTM)-54.07%
Revenue growth 3Y99.36%
Revenue growth 5Y97.22%
Sales Q2Q%39.04%
Revenue Next Year-38.3%
Revenue Next 2Y-22.61%
Revenue Next 3Y-15.82%
Revenue Next 5Y-4.48%
EBIT growth 1Y-120.59%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-206.81%
EBIT Next 3Y-45%
EBIT Next 5Y-6.64%
FCF growth 1Y-92.1%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-87.88%
OCF growth 3YN/A
OCF growth 5YN/A